

1 **Persistence of immunity against omicron BA.1 and BA.2 following**  
2 **homologous and heterologous COVID-19 booster vaccines in**  
3 **healthy adults after a two-doses AZD1222 vaccination**

4 Suvichada Assawakosri<sup>a,b</sup>, Sitthichai Kanokudom<sup>a,b</sup>, Jira Chansaenroj<sup>a</sup>, Nungruthai  
5 Suntronwong<sup>a</sup>, Chompoonut Auphimai<sup>a</sup>, Pornjarim Nilyanimit<sup>a</sup>, Preeyaporn Vichaiwattana<sup>a</sup>,  
6 Thanunrat Thongmee<sup>a</sup>, Thaneeya Duangchinda<sup>c</sup>, Warangkana Chantima<sup>d,e</sup>, Pattarakul  
7 Pakchotanon<sup>c</sup>, Donchida Srimuan<sup>a</sup>, Thaksaporn Thatsanatorn<sup>a</sup>, Sirapa Klinfueng<sup>a</sup>, Natthinee  
8 Sudhinaraset<sup>a</sup>, Nasamon Wanlapakorn<sup>a</sup>, Juthathip Mongkolsapaya<sup>f,g</sup>, Sittisak Honsawek<sup>b\*</sup>, Yong  
9 Poovorawan<sup>a,h\*</sup>

10 <sup>a</sup> Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,  
11 Bangkok, 10330, Thailand

12 <sup>b</sup> Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,  
13 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,  
14 Bangkok, 10330, Thailand

15 <sup>c</sup> Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic  
16 Engineering and Biotechnology (BIOTEC), National Science and Development Agency,  
17 NSTDA, Pathum Thani 12120, Thailand

18 <sup>d</sup> Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital,  
19 Mahidol University, Bangkok 10700, Thailand

20 <sup>e</sup> Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of  
21 Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

22 <sup>f</sup> Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,  
23 Oxford, OX3 7BN, UK

24 <sup>g</sup> Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford,  
25 Oxford, UK.

26 <sup>h</sup> FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

27 \*Address correspondence to

28 Prof. Dr. Yong Poovorawan, Center of Excellence in Clinical Virology, Department of  
29 Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand. E-mail:  
30 yong.p@chula.ac.th

31 Prof. Dr. Sittisak Honsawek, Center of Excellence in Osteoarthritis and Musculoskeleton,  
32 Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai  
33 Red Cross Society, Bangkok, 10330, Thailand E-mail: Sittisak.h@chula.ac.th

34 **Abstract**

35 **Objectives:** The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to  
36 evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study  
37 aimed to provide evidence on a heterologous booster strategy to overcome the waning immunity  
38 against Omicron variants.

39 **Methods:** Participants who completed Oxford/AstraZeneca (hereafter AZD1222) for 5-7 months  
40 were enrolled. The reactogenicity and persistence of immunogenicity in both humoral and  
41 cellular response after a homologous or heterologous booster with the AZD1222 and mRNA  
42 vaccines (BNT162B2, full or half-dose mRNA-1273) administered six months after primary  
43 vaccination were determined.

44 **Results:** Total 229 individuals enrolled, a waning of immunity was observed 5-7 months after  
45 the AZD1222-primed. Total RBD immunoglobulin (Ig) levels, anti-RBD IgG and focus  
46 reduction neutralization test against Omicron BA.1 and BA.2 and T cell response peaked 14-28  
47 days after booster vaccination. Both the full and half dose of mRNA-1273 induced the highest  
48 response, followed by BNT162b2 and AZD1222. At 90 days, the persistence of immunogenicity  
49 was observed among all mRNA-boosted individuals. Adverse events were acceptable and well  
50 tolerated for all vaccines.

51 **Conclusions:** A heterologous mRNA booster provided a significantly superior boost of binding  
52 and NAbs levels against the Omicron variant compared to a homologous booster in individuals  
53 with AZD1222-primed vaccinations.

54 **Keywords** COVID-19; AZD1222; heterologous booster; omicron; neutralizing antibody; T  
55 cells.

56 **Introduction**

57 Since the first emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
58 Omicron (BA.1/B.1.1.529) variant in November 2021, it has rapidly spread and became the  
59 dominant variant circulating worldwide (WHO, 2022a, WHO HQ, 2022). The Omicron variant  
60 harbors mutations within the Spike (S) protein, particularly 15 amino acid substitutions in the  
61 receptor-binding domain (RBD) (Viana et al., 2022). Mutations within the RBD of the omicron  
62 variant mediate antibody evasion and greatly increase transmissibility through enhanced affinity  
63 for the angiotensin-converting enzyme 2 receptor (ACE2) (Mannar et al., 2022, McCallum et al.,  
64 2022, Tian et al., 2021). Recently, the Omicron variant was further classified into several  
65 descendent sublineages, including BA.1, BA.1.1, BA.2, BA.2.2, and BA.3. (Viana et al., 2022).  
66 As of March 2022, epidemiological data have suggested that BA.2 sublineages have been the  
67 most common sublineage of Omicron worldwide, including the South-East Asia region (WHO,  
68 2022b). Furthermore, like Thailand, epidemiological surveillance revealed that the proportion of  
69 the BA.2 variant has increased and represented >90% of all positive cases reported since March  
70 2022 (Puenpa et al., 2022). BA.1 and BA.2 share multiple mutations, but BA.2 also presents  
71 unique viral characteristics of BA.1, such as higher reproduction rate, fusogenicity, and  
72 pathogenicity (Viana et al., 2022, Yamasoba et al., 2022). Scientific knowledge on the difference  
73 in ability between BA.1 and BA.2 to evade third dose vaccine-induced immunity is still limited.  
74 Several coronavirus diseases 2019 (COVID-19) vaccines have been developed to combat the  
75 COVID-19 infection. The AZD1222 vaccine has been the highly used vaccine accounting for 2.8  
76 billion doses administered worldwide and 48.3 million doses in Thailand alone (AstraZeneca  
77 PLC, 2022, MOPH, 2022). Although the vaccine effectiveness (VE) after two-dose AZD1222  
78 was estimated at 64%–74.0% for preventing SARS-CoV-2 and other lineage infection (Clemens

79 et al., 2021, Falsey et al., 2021), waning of vaccine-induced immunity of both anti-IgG and the  
80 NAbs from AZD1222-primed vaccinees has been documented. For example, the dramatically  
81 decreased levels of NAbs after 5-6 months of two doses of AZD1222 vaccination showed an  
82 inadequate response to control the spread of SARS-CoV-2, especially the Omicron variant  
83 (Dejnirattisai et al., 2022, Planas et al., 2022, Shrotri et al., 2021). Like a previous study, NAbs  
84 decreased substantially after six months of vaccination with BNT162b2 (Dejnirattisai et al.,  
85 2022). Furthermore, the increase in infection was related to the waning immunity as a function of  
86 time after BNT162b2-priming (Goldberg et al., 2021, Levin et al., 2021). Thus, the decline in  
87 vaccine-induced immunity markedly increased a few months after vaccination and may be the  
88 potential cause of breakthrough infection.

89 There is a growing interest in using booster dose as a new strategy to combat waning immunity  
90 after primary vaccination and the high transmissibility and immune evasion of the omicron  
91 sublineages. To date, increasing evidence has supported that the booster dose of the mRNA  
92 vaccine following BNT162b2-priming significantly increased protection against the Omicron  
93 variant (Garcia-Beltran et al., 2022). Furthermore, a heterologous booster after six months of  
94 two-dose CoronaVac demonstrated that a heterologous booster produced stronger immunity than  
95 a homologous booster (Assawakosri et al., 2022). In individuals primed with AZD1222, a  
96 heterologous boost with BNT162b2 exhibited more effectiveness in inducing NAbs against BA.1  
97 than the homologous booster with AZD1222 (Dejnirattisai et al., 2022), but there were no data  
98 against BA.2. These results implied that the heterologous booster strategy could provide stronger  
99 immunity against Omicron infection. However, very limited knowledge is available on the  
100 duration of immune protection after the third homologous or heterologous dose and when we  
101 should consider an additional booster beyond the third dose.

102 Consequently, our objective was to study the persistence of immunogenicity beyond one month  
103 following the third dose. In the same cohort, we also investigated NAb against the new emerging  
104 omicron variant, particularly the BA.2 sublineage, the cellular response and the reactogenicity  
105 after the homologous and heterologous booster dose administered at 6-month intervals in healthy  
106 adults who were previously vaccinated with AZD1222.

## 107 **MATERIALS AND METHODS**

### 108 **Study design**

109 This prospective cohort study was conducted at the Clinical Trial Unit, the Center of Excellence  
110 in Clinical Virology of Chulalongkorn University, Bangkok, Thailand, and was performed in  
111 accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice  
112 Guidelines (ICH-GCP). The participants were informed, and written consent was obtained before  
113 enrollment.

### 114 **Study participants**

115 Between November 2021 and January 2022, a total of 229 subjects participated in this  
116 prospective cohort study. The main inclusion criteria were: Thai adults over 18 years of age with  
117 no previous or current diagnosis of COVID-19 infection and completed a two-dose vaccination  
118 of the AZD1222 at an interval of 5-7 months during the enrollment period. The intervals between  
119 two-dose AZD1222-primed were 8-10 weeks. In addition, participants with an autoimmune or  
120 cancer disease, taking immunosuppressive drugs, or participants that were pregnant or  
121 breastfeeding were excluded.

## 122 **Study vaccine**

123 All participants were divided into four groups by conveniently sampling 50-60 participants per  
124 group based on vaccine availability and vaccinated with one of the following preparations;  
125 including 1) viral vector: AZD1222 (AstraZeneca, Oxford, UK) (Folegatti et al., 2020), 2)  
126 mRNA: BNT162b2 (Pfizer-BioNTech Inc., New York City, NY), 3) mRNA: 100 µg mRNA-  
127 1273 (full-dose group) (Moderna Inc., Cambridge, MA), and 4) 50 µg mRNA-1273 (half-dose  
128 group) (Jackson et al., 2020). The study flow is illustrated in Figure 1.

## 129 **Reactogenicity Assessment**

130 All participants were observed under the supervision of doctors after vaccination to prevent  
131 anaphylaxis reactions. Participants received an online or paper-based self-monitoring record  
132 survey seven days after vaccination. They observed the solicited local and systemic AEs,  
133 including injection site pain, induration, redness, fever, headache, myalgia, arthralgia, nausea,  
134 and vomiting.

## 135 **Sample collection, total RBD Ig, and anti-RBD IgG/nucleocapsid assay**

136 Blood samples from vaccinees were collected prior to vaccination and at every follow-up visit on  
137 days 14, 28, and 90 after the booster dose. The samples of all participants were tested for  
138 quantitative antibody levels of total RBD Ig using Elecsys SARS-CoV-2 S (Roche Diagnostics,  
139 Basel, Switzerland), anti-RBD IgG, and anti-nucleocapsid IgG (anti-N IgG) using the SARS-  
140 CoV-2 IgG assay (Abbott, Sligo, Ireland) (Kanokudom et al., 2022).

## 141 **Surrogate virus neutralization assay for delta and omicron variants**

142 A cPass<sup>TM</sup> SARS-CoV-2 surrogate virus neutralization test (GenScript Biotech, New Jersey) was  
143 used to measure NAb titers against SARS-CoV-2 variants. Recombinant RBD from delta and  
144 omicron strains and 96-well plates coated with recombinant human ACE2 was used

145 (Kanokudom et al., 2022). The percentage of inhibition of a sample was calculated, samples with  
146 percent inhibition  $\geq 30\%$  were considered a “seropositive” for SARS-CoV-2 neutralizing  
147 antibodies.

#### 148 **Focus reduction neutralization test (FRNT50)**

149 The neutralization antibody titers against the variants BA.1 and BA.2 of SARS-CoV-2 Omicron  
150 were measured. The Focus reduction neutralization assay was performed (Assawakosri et al.,  
151 2022). The nucleotide sequences of the BA.1 and BA.2 variants are deposited in GenBank under  
152 accession numbers: EPI\_ISL\_8547017 for BA.1 and EPI\_ISL\_11698090 for BA.2 variant. The  
153 50% focus reduction percentage was calculated, and the inhibitory concentration (IC<sub>50</sub>) was  
154 determined using PROBIT software. The detection limit of the assay is 1:20, and the NAb  
155 values below the limit were substituted with a titer of 10.

#### 156 **Interferon-gamma release assay.**

157 The interferon-gamma (IFN- $\gamma$ ) release assay was performed to evaluate cell-mediated immunity  
158 using QuantiFERON (QFN) SARS-CoV-2 RUO (Qiagen, Hilden, Germany) (Kanokudom et al.,  
159 2022). Briefly, heparinized whole blood was added to a spike-peptides-coated tube (Ag1) to  
160 stimulate CD4<sup>+</sup> and (Ag2) to stimulate CD4<sup>+</sup>, and CD8<sup>+</sup> T cells then incubated for 21 hours.  
161 Plasma samples were then collected to measure IFN- $\gamma$  levels by ELISA (Munro et al.). The IFN-  
162  $\gamma$  levels were expressed in IU IFN- $\gamma$ /mL. Levels above 0.15 IU/mL were defined as seropositive.

#### 163 **Statistical analysis**

164 G\*power software version 3.1.9.6 was used to calculate the sample size. All statistical analyses  
165 were conducted using the Statistical Package for the Social Sciences (SPSS) v.22 (SPSS Inc.,  
166 Chicago, IL, USA). Figures were generated using GraphPad Prism v9.0 (GraphPad Software,



167 San Diego, CA, USA) and R v4.1.2. Software (R Foundation for Statistical Computing, Vienna,  
168 Austria). Binding antibody and NAbs were logarithmically transformed, and comparison  
169 between groups was performed using analysis of variance (Folegatti et al.) with Bonferroni  
170 adjustment or Kruskal-Wallis H test for nonparametric data. The qualitative data comparison was  
171 performed using Pearson's  $\chi^2$  or Fisher's exact test. The Wilcoxon signed rank test was used for  
172 pairwise analysis. A  $p$ -value  $<0.05$  was considered statistically significant.

## 173 **RESULTS**

### 174 **Demographic data**

175 From November 2021 to January 2022, 229 adults were enrolled in the study. All participants  
176 were healthy Thai adults with a mean age of 50.05 ( $\pm 9.71$ ) years, 55.72 ( $\pm 13.68$ ) years, 50.66  
177 ( $\pm 12.95$ ) years, and 57.02 ( $\pm 12.28$ ) years in group AZD1222, BNT162b2, full-dose mRNA-1273  
178 and half-dose mRNA-1273, respectively. Most participants were female, 127 (55.5%)  
179 participants, and the average interval between the second dose and the booster dose was 166.3  
180 (128-229) days. Common comorbidities included dyslipidemia, hypertension, diabetes mellitus,  
181 and allergy. Generally, the groups did not have significant differences in baseline characteristics,  
182 including sex and common underlying diseases and the intervals between follow-up times.  
183 However, the age of BNT162b2 and half-dose mRNA-1273 was significantly higher than that of  
184 AZD1222 and mRNA-1273 arms. Participant characteristics are shown in Table 1. During the  
185 study, 38 participants were lost to follow-up, five participants were excluded because they tested  
186 positive for SARS-CoV-2 infection, and another five participants were excluded because they  
187 had received a fourth vaccine dose.

188 **Immunogenicity assessment**

189 **Total RBD Ig and anti-RBD IgG**

190 There were no differences in total RBD Ig and anti-RBD IgG between four groups at baseline,  
191 with geometric mean titer (GMT) 244 U/mL and 50.2 BAU/mL, respectively. Most participants  
192 had a very low antibody titer at 5–7 months after completing the second AZD1222 vaccination.  
193 However, 14 days after boost, total RBD Ig levels were significantly elevated to 2069, 13651,  
194 28172, and 25824 U/mL in the AZD1222, BNT162b2, mRNA-1273, and half-dose groups,  
195 respectively (Figure 2A). Comparable trends with anti-RBD IgG levels were observed with  
196 GMT 268, 2285, 3864, and 3976 BAU/mL (Figure 2B). It should be noted that the concentration  
197 of total RBD Ig decreased to 1303, 3974, 5516, and 6120 U/mL 90 days after the third dose in  
198 each group, respectively. The mRNA-1273 vaccine produced the highest immune response  
199 among all booster groups, followed by BNT162b2 and AZD1222, respectively. In comparison,  
200 the GMT of total RBD Ig and IgG against RBD between full- and half-dose mRNA-1273 were  
201 comparable at both 14 and 90 days (Supplementary Table 1). Anti-N IgG levels were also  
202 measured. In this study, the anti-N IgG results showed that all participants were seronegative (cut  
203 off 1.4) to anti-N IgG at each visit (Supplementary Figure 1).

204 **Surrogate virus neutralization specific delta and Omicron variants**

205 The sVNT against the Delta and Omicron variants was performed randomly in half of the  
206 participants of each group. A subset of the sample was tested for Surrogate virus neutralization  
207 (sVNT) in the pre-booster. At 28 days after boosters, the median percentage inhibition to the  
208 Delta variant was significantly elevated to 93.5% in AZD1222, 96.9% in BNT162b2, 97.0% in  
209 mRNA-1273 and 97.9% in half dose mRNA-1273 (Figure 3A). While a lower percentage of  
210 inhibition was observed against Omicron variants with 15.0%, 67.1%, 64.6%, and 65.7% in

211 groups AZD1222, BNT162b2, mRNA-1273, and half-dose mRNA-1273, respectively (Figure  
212 3B). These results suggested that heterologous boosted individuals achieved a higher level of  
213 NAb against the Omicron variant than homologous boosted individuals. On day 90 after  
214 vaccination, the median percentage of inhibition to the Delta variant decreased slightly to 78.0%  
215 in the AZD1222-boosted group, while the other groups remained >97% inhibition. In contrast to  
216 the Omicron variant, the median percentage inhibition was reduced to 9.0% for AZD1222,  
217 33.2% for BNT162b2, 35.5% for mRNA-1273, and 38.7% for half-dose groups of mRNA-1273,  
218 respectively. Correspondingly, the neutralizing activity against the Omicron variant was  
219 significantly lower than that against the Delta variant (Figure 3C). The heterologous  
220 AZD1222/mRNA prime-boosted achieved higher detectable neutralization activities against  
221 omicron than the homologous boost at both the 28-day and 90-day timepoint (Supplementary  
222 Table 2).

### 223 **Focus reduction neutralization test**

224 We determined the cross-neutralizing activity of NAbs against the BA.1 and BA.2 Omicron  
225 variants after booster vaccination using the Focus reduction neutralization assay (FRNT50) in a  
226 subset of samples. Most participants showed undetectable Nabs on day 0 with 75.0%, 100%,  
227 45%, and 60% in each group. The GMT of NAbs against BA.1 was 32.2 (20.1-51.6), 166 (114-  
228 243), 548 (415-723), and 396 (275-571) 28 days after receiving AZD1222, BNT162b2, mRNA-  
229 1273, and half-dose mRNA-1273, respectively (Figure 4A). Similarly, GMTs of Nabs against  
230 BA.2 were 45.6 (28.8-72.3), 248 (179-342), 324 (214-492), and 224 (156-322), respectively  
231 (Figure 4B). Then, 90 days post-vaccination, the GMT levels decreased to 21.6 (13.5-34.8),  
232 87.0 (54.5-139), 141(89.6-222), 119 (78.5-181) for BA.1 and 32.6 (22.0-48.3), 73.8 (56.1-  
233 97.2), 139 (85.6-226), 111 (75-163) for BA.2 in group, respectively. The NAb titers to BA.1

234 were comparable to BA.2 (Figure 4C-4D). Furthermore, higher activity was observed to  
235 neutralize the omicron variant in the heterologous mRNA boosted than in homologous boosted  
236 individuals.

### 237 **Total interferon-gamma response**

238 The IFN- $\gamma$  release assay was used to measure the presence of T cell responses, for both CD4+  
239 and CD8+ T cells. On day 0, the total IFN- $\gamma$  level produced by CD4+/CD4+ and CD8+ was less  
240 observed in 29/116 (25.0%) and 43/116 (37.1%) of all participants. Conversely, the  
241 seropositivity rate for Ag1 CD4+ rapidly increased to 79.3% for BNT162b2, 89.3% for  
242 mRNA-1273, 89.3% for the half-dose group on day 14, while the seropositivity rate for Ag2  
243 CD4+ and CD8 + was 86.2%, 89.3% and 92.9%, respectively. Then it slightly decreased at 28  
244 days after boosted (Figure 5A and 5B). The highest seropositivity rate in AZD1222-boosted  
245 was 37.9% and 69.0%, indicating that AZD1222-boosted produced a lower T cell response  
246 than the mRNA-boosted. Moreover, the persistence of T cell response was observed among  
247 mRNA-boosted individuals on day 90 after vaccination, but not in AZD1222-boosted  
248 individuals. Consequently, heterologous mRNA boost exhibited a stronger positive impact on T-  
249 cell responses than the homologous booster in individuals previously vaccinated with AZD1222.  
250 The levels of IFN- $\gamma$  among all groups are summarized in Supplementary Table 3.

### 251 **Reactogenicity assessment**

252 Reactogenicities following the booster vaccination were as follows: the most common local  
253 vaccine reaction in the first seven days was injection site pain while the most common systemic  
254 reaction was myalgia (Figure 6A–6D). Comparison of AEs between groups revealed that the  
255 injection site pain, myalgia, and chilling were lower in individuals receiving AZD1222 than in  
256 other vaccines (Supplementary Figure 2A-C). However, most incidences of AE were reported as

257 mild-to-moderate in severity and resolved a few days after vaccination. Furthermore, the local  
258 reactions AE was less frequent in half-dose mRNA-1273 than in full dose included injection site  
259 pain (98.3% vs 86.0%), and swelling (20.8% vs. 30.0%). During the study period, no serious  
260 adverse effects were observed among all groups. The summarize data of all AE were shown in  
261 Supplementary Table 4.

## 262 **Discussion**

263 Herein, we report quantifications of total RBD Ig, anti-RBD IgG, Nab, and total IFN- $\gamma$  levels  
264 after homologous and heterologous booster in participants who received two doses of AZD1222  
265 vaccine. We also show the reactogenicity profile of all vaccine boosters. We determined there  
266 was a significant increase in total Ig, anti-RBD IgG, neutralizing antibody, and cellular responses  
267 14-28 days after the booster shot. The decay of the immune response was observed 90 days after  
268 the initial boosted for all study arms. At 7 days after vaccination, all COVID-19 vaccines  
269 administered as a booster dose had acceptable reactogenicity with mild to moderate AE and  
270 generally resolved within a few days after vaccination. AE data indicated that homologous and  
271 heterologous vaccine boosters presented a good safety profile in all healthy adults, consistent  
272 with the previous study of third homologous and heterologous boosters in individuals primed  
273 with the AZD-1222 or BNT162b2 vaccines (Flaxman et al., 2021, Munro et al., 2021).

274 Our findings revealed that following the first primary series of AZD1222, a waning immunity  
275 was evidenced 5-7 months after vaccination. After the booster was implemented with both  
276 homologous and heterologous vaccines, antibody binding levels increased significantly  
277 compared to baseline. Half-dose mRNA-1273 elicited total Ig and IgG RBD responses equal to  
278 the full-dose group, which is consistent with the previous observation of mRNA-1273 booster in  
279 participants primed with two-doses of mRNA-1273 (Choi et al., 2021). Furthermore, individuals

280 boosted with full and half doses of mRNA-1273 possessed the highest levels of total RBD Ig and  
281 anti-RBD IgG compared to those boosted with BNT162b2 and AZD1222. According to the  
282 COV-BOOST study, the magnitude of anti-spike IgG in individuals receiving a heterologous  
283 booster was significantly higher than the homologous booster (Munro et al., 2021). In addition,  
284 similar results have been reported previously regarding the heterologous third dose in individuals  
285 receiving triple inactivated or triple mRNA vaccine (Gagne et al., 2022, Liu et al., 2022, Wang et  
286 al., 2022). Our results may suggest that a single shot heterologous booster could further enhance  
287 the immune response by stimulating the memory B-cell response (Goel et al., 2021).

288 In accordance with those recent report from the UK, we found that NAbs after 5-7 months of  
289 AZD1222-primed individuals rapidly waned to near or below the detection limit and were barely  
290 neutralized against Delta and Omicron variants (Wu et al., 2022). Herein, we observed that the  
291 heterologous mRNA-based booster, but not the AZD1222-boosted, effectively produced a high  
292 level of cross-neutralization against SARS-CoV-2 variants 28 days after the booster dose. The  
293 breadth and cross-reactivity of NAbs after the third dose may be related to increasing memory B  
294 cell affinity maturation through extensive somatic hypermutation like those observed in a  
295 previous mRNA-boosted study (Paschold et al., 2022). However, reductions in neutralizing  
296 activity against Omicron variants were found compared with those against Delta variants, in both  
297 BNT162b2-primed and CoronaVac-primed individuals (Assawakosri et al., 2022, Pérez-Then et  
298 al., 2022, Planas et al., 2022). Although the BA.2 sublineage was documented to have different  
299 viral characteristics than BA.1. Our findings revealed that the neutralizing activity against the  
300 BA.1 and BA.2 variants was comparable. These results are consistent with previous studies  
301 indicating that BA.2 was only 1.4-fold lower in NAbs than the BA.1 variant after BNT62b2  
302 booster in BNT162b2-primed and previously infected individuals (Chen et al., 2022, Yu et al.,

303 2022). Our finding indicated that mRNA vaccines encoding the ancestral strain-spike could  
304 induce a potent cross-neutralizing antibody against Delta, Omicron, both BA.1 and BA.2  
305 subvariants.

306 Since the NAbs are the leading correlation with protection against COVID-19 infection (Khoury  
307 et al., 2021). In our cohort, individuals boosted with mRNA possessed high levels of NAbs titer  
308 against BA.1 and BA.2 subvariants. The high NAb titers observed in this study were related to  
309 the increase in VE protection against symptomatic disease caused by the Omicron and Delta  
310 variants after mRNA booster vaccination among the AZD1222-primed individuals (Andrews et  
311 al., 2022). Although >90% of all participants had detectable neutralizing antibody responses after  
312 90 days of booster vaccination, the reduction in NAbs titers against the Omicron variant was  
313 evident. Similarly, VE data substantially decreased from 70.1% to 60.9% in mRNA-1273-  
314 boosted and 62.4% to 39.6% in BNT162b2-boosted after 10 or more weeks of booster (Andrews  
315 et al., 2022). Since there is an evident benefit of a fourth dose seven months after the third dose  
316 (Munro et al., 2022), the result showed that the fourth booster elicited a high level of anti-spike  
317 IgG in individuals receiving AZD1222/mRNA prime boosters. The additional fourth dose should  
318 be optional for those who received the AZD1222 as the third dose due to the lower antibody  
319 response in this group.

320 Besides humoral immune responses, vaccine-induced T cell responses have a potential role in  
321 cross-recognizing Alpha, Beta, Delta, and Omicron variants even if using a different vaccination  
322 regimen (Gao et al., 2022, Jarjour et al., 2021, Tarke et al., 2021). Because class I and II spike  
323 epitopes were 70-80% conserved, leading to the preservation of CD4+ and CD8+ T cell  
324 responses (Tarke et al., 2021). Thus, the CD4 + and CD8+ T cells responses have remained  
325 stable primarily in frequency and magnitude against all variants of concern. Our study showed

326 the CD4+ and CD8+ T cell-producing IFN- $\gamma$  were rapidly restored after 14 days of the  
327 heterologous booster vaccination. Additionally, >70% of the mRNA-boosted individuals  
328 demonstrated seropositive for T cell-producing IFN- $\gamma$  response after 90 days post-vaccination but  
329 showed only 50% seropositive for T cell-producing IFN- $\gamma$  response in AZD1222-boosted group.  
330 Beyond humoral responses, the heterologous booster could enhance the adaptive T-cell response,  
331 and the T-cell response may play an essential role as a second-level cross-protection against  
332 other upcoming variants.

333 Potential limitations of our study include may be attributed to the loss of some participants  
334 during follow-up. Moreover, the phenotype of CD4+ and CD 8+ T cells was not examined after  
335 booster vaccination. Additional studies of 6-month and longer duration are needed to address the  
336 long-term durability of the immune response to booster vaccination.

337 In conclusion, the heterologous mRNA vaccine has an acceptable safety profile and could  
338 significantly enhance humoral and cellular responses after vaccination in AZD1222-primed  
339 individuals. Additionally, the booster with full-dose and half-dose mRNA-1273 exhibited the  
340 highest humoral and cellular immune responses at 90 days after the booster dose, followed by  
341 BNT162b2 and AZD1222. Receiving a heterologous booster dose could provide immune  
342 protection against new emerging SARS-CoV-2 variants.



343 **Ethics approval and consent to participate**

344 The study protocol was approved by the Institutional Review Board of the Faculty of Medicine  
345 of Chulalongkorn University (IRB numbers 690/64). The study was registered with the Thai  
346 Clinical Trials Registry (TCTR 20210910002).

347 **Conflicts of Interest**

348 The authors declare no conflict of interest.

349 **Funding Statement**

350 This work was supported by the Health Systems Research Institute (HSRI), National Research  
351 Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn  
352 University, and King Chulalongkorn Memorial Hospital and was partially supported by the  
353 Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported  
354 by National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No.  
355 P2051613).

356 **Acknowledgments**

357 The authors are grateful for the Center of Excellence in Clinical Virology staff and all the  
358 participants for helping and supporting this project. We also thank the Ministry of Public Health,  
359 Chulabhorn Royal Academy, and Zullig pharma for providing the vaccines for this study.

360 **Reference list**

- 361 Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine  
362 Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med*.  
363 2022;386(16):1532-46.
- 364 Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et  
365 al. Neutralizing Activities against the Omicron Variant after a Heterologous Booster in  
366 Healthy Adults Receiving Two Doses of CoronaVac Vaccination. *J. Infect. Dis.* 2022.  
367 Doi: 10.1093/infdis/jiac092
- 368 AstraZeneca PLC. First quarter 2022 results; 2022. Available from:  
369 [https://www.astrazeneca.com/content/dam/az/PDF/2022/q1-2022/Q1-2022-results-](https://www.astrazeneca.com/content/dam/az/PDF/2022/q1-2022/Q1-2022-results-announcement.pdf)  
370 [announcement.pdf](https://www.astrazeneca.com/content/dam/az/PDF/2022/q1-2022/Q1-2022-results-announcement.pdf).
- 371 Chen L-L, Chu AW-H, Zhang RR-Q, Hung IF-N, To KK-W. Serum neutralisation of the SARS-  
372 CoV-2 omicron sublineage BA.2. *Lancet Microbe*. 2022;3(6):e404.
- 373 Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-  
374 2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat. Med*.  
375 2021;27(11):2025-31.
- 376 Clemens SAC, Folegatti PM, Emary KRW, Weckx LY, Ratcliff J, Bibi S, et al. Efficacy of  
377 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in  
378 Brazil. *Nat. Commun*. 2021;12(1):5861.
- 379 Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.  
380 1.1. 529 leads to widespread escape from neutralizing antibody responses. *Cell*.  
381 2022;185(3):467-84.e15.
- 382 Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and  
383 Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med*.  
384 2021;385(25):2348-60.
- 385 Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and  
386 immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the  
387 UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet*.  
388 2021;398(10304):981-90.
- 389 Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and  
390 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary  
391 report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*.  
392 2020;396(10249):467-78.
- 393 Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, et al. mRNA-1273 or  
394 mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion,  
395 neutralizing antibodies and protection against Omicron. *Cell*. 2022;185(9):1556-71.e18.
- 396 Gao Y, Cai C, Grifoni A, Müller T, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-specific  
397 T cells cross-recognize the Omicron variant. *Nat. Med*. 2022;28(3):472-76.
- 398 Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al.  
399 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-  
400 CoV-2 Omicron variant. *Cell*. 2022;185(3):457-66.e4.
- 401 Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct  
402 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals  
403 following mRNA vaccination. *Sci Immunol*. 2021;6(58):eabi6950.

- 404 Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning  
405 Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med.* 2021;385(24):e85.
- 406 Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA  
407 Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med.* 2020;383(20):1920-  
408 31.
- 409 Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19. *Immunity*  
410 2021;54(1):14-8.
- 411 Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et  
412 al. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector,  
413 and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated  
414 Vaccine. *Vaccines* 2022;10(1):86.
- 415 Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing  
416 antibody levels are highly predictive of immune protection from symptomatic SARS-  
417 CoV-2 infection. *Nat. Med.* 2021;27(7):1205-11.
- 418 Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral  
419 Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med.*  
420 2021;385(24):e84.
- 421 Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D, et al. Robust induction of B cell and T cell responses  
422 by a third dose of inactivated SARS-CoV-2 vaccine. *Cell Discov.* 2022;8(1):10.
- 423 Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Tuttle KS, et al. SARS-CoV-2  
424 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2  
425 complex. *Science.* 2022;375(6582):760-4.
- 426 McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. Structural  
427 basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science.*  
428 2022;375(6583):864-8.
- 429 Misnistry of Public Heath, Department of Disease Control; COVID-19 vaccine reported.  
430 <https://ddc.moph.go.th/dcd/pagecontent.php?page=641&dept=dcd> (accessed 15 May  
431 2022)
- 432 Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and  
433 immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two  
434 doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded,  
435 multicentre, randomised, controlled, phase 2 trial. *Lancet.* 2021;398(10318):2258-76.
- 436 Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity,  
437 and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-  
438 dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose  
439 of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised t. *Lancet*  
440 *Infect Dis.* 2022;S1473-3099(22)00271-7.
- 441 Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, et al. Rapid  
442 hypermutation B cell trajectory recruits previously primed B cells upon third SARS-  
443 CoV-2 mRNA vaccination. *Front Immunol.* 2022;13:876306.
- 444 Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Neutralizing  
445 antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous  
446 CoronaVac plus BNT162b2 booster vaccination. *Nat. Med.* 2022;28(3):481-5.
- 447 Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al.  
448 Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*  
449 2022;602(7898):671-5.


- 450 Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al.  
451 Molecular characterisation and tracking of the severe acute respiratory syndrome  
452 coronavirus 2, Thailand, 2020–2022. Research Square Platform LLC; 2022.
- 453 Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody  
454 waning after second dose of BNT162b2 or ChAdOx1. *Lancet*. 2021;398(10298):385-7.
- 455 Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination  
456 induces immunological memory able to cross-recognize variants from Alpha to Omicron.  
457 *bioRxiv* 2021. Doi:10.1101/2021.12.28.474333
- 458 Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, et al. N501Y mutation of spike protein in  
459 SARS-CoV-2 strengthens its binding to receptor ACE2. *Elife*. 2021;10:e69091.
- 460 Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic  
461 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*  
462 2022;603(7902):679-86.
- 463 Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, et al. Memory B cell repertoire from triple  
464 vaccinees against diverse SARS-CoV-2 variants. *Nature* 2022;603(7903):919-25.
- 465 WHO. Statement on Omicron sublineage BA.2; 2022a. Available from:  
466 <https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2>.  
467 (Accessed March 23 2022).
- 468 WHO. COVID-19 Weekly Epidemiological Update Edition: World Health Organization (WHO).  
469 2022b. [Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---5-april-2022>. (Accessed April 8 2022)
- 470  
471 WHO HQ. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions  
472 for Member States. Available from: [https://www.who.int/docs/default-source/coronaviruse/20211217-global-technical-brief-and-priority-action-on-omicron\\_latest-2.pdf?sfvrsn=bdd8297c\\_12](https://www.who.int/docs/default-source/coronaviruse/20211217-global-technical-brief-and-priority-action-on-omicron_latest-2.pdf?sfvrsn=bdd8297c_12). (Accessed March 23 2022).
- 473  
474  
475 Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccination  
476 elicits neutralising antibodies against omicron. *Lancet*. 2022;399(10326):715-7.
- 477 Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of  
478 SARS-CoV-2 BA.2 variant. *Cell*. 2022;S0092-8674(22)00533-5.
- 479 Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the SARS-  
480 CoV-2 Omicron BA.1 and BA.2 Variants. *N Engl J Med*. 2022;386(16):1579-80.

481 **Table 1: Baseline characteristics of the participants enrolled in this study.**

	<b>Total</b>	<b>AZD1222</b>	<b>BNT162b2</b>	<b>mRNA-1273</b>	<b>Half mRNA-1273</b>
<b>Total number (n)</b>	229	59	61	59	50
<b>Age ± SD (year)</b>					
<b>Mean ± SD</b>	53.24±12.55	50.05±9.71	55.72±13.68	50.66±12.95	57.02±12.28
<b>Sex</b>					
<b>Male (%)</b>	102 (44.5%)	23 (39.0%)	26 (42.6%)	30 (50.8%)	23 (46.0%)
<b>Female (%)</b>	127 (55.5%)	36 (61.0%)	35 (57.4%)	29 (49.2%)	27 (54.0%)
<b>Underlying diseases (%)</b>					
<b>Allergy</b>	14 (6.1%)	5 (8.5%)	5 (8.2%)	3 (5.1%)	1 (2.0%)
<b>Cardiovascular diseases</b>	4 (1.7%)	3 (5.1%)	1 (1.6%)	0 (0.0%)	0 (0.0%)
<b>Diabetes Mellitus</b>	19 (8.3%)	2 (3.4%)	8 (13.1%)	5 (8.5%)	4 (8.0%)
<b>Dyslipidemia</b>	46 (20.1%)	6 (10.2%)	17 (27.9%)	10 (16.9%)	13 (26.0%)
<b>Hypertension</b>	46 (20.1%)	9 (15.3%)	17 (27.9%)	7 (11.9%)	13 (26.0%)
<b>Thyroid</b>	4 (1.7%)	1 (1.7%)	3 (4.9%)	0 (0.0%)	0 (0.0%)
<b>Others</b>	20 (8.7%)	7 (11.9%)	10 (16.4%)	3 (5.1%)	0 (0.0%)
<b>Follow-up Time</b>					
<b>Second visit</b>					
<b>Mean (range) day</b>	14.7 (12-20)	14.6 (14-20)	16.0 (14-19)	14.1 (13-15)	14.0 (12-21)
<b>Third visit</b>					
<b>Mean (range) day</b>	29.9 (21-39)	28.9 (28-36)	29.9 (26-39)	28.2 (26-30)	33.2 (21-35)
<b>Fourth visit</b>					
<b>Mean (range) day</b>	94.5 (89-114)	90.3 (90-92)	102.8 (93-114)	91.8 (89-100)	94.4 (90-104)

482

483 **Figure**



484

485 **Figure 1. Diagram of the number of included participants and study groups.** A total of 229


486 individuals who were previously vaccinated with AZD1222 were enrolled to analyze binding

487 antibodies and T cell responses in the cohort study. Blood samples were collected at 0, 14, 28,


488 and 90 days after booster vaccination. They were assigned to receive a booster vaccine including

489 AZD1222 (n=59) or BNT162b2 (n=61) or mRNA-1273 (n=59) or half-dose mRNA-1273

490 (n=50).




491 **Figure 2: Measurement of the SARS-CoV-2-specific binding antibody.** (A) shows the total  
 492 RBD Ig (U/mL). (B) displays the anti-RBD IgG (BAU/mL). Each data point represents the level  
 493 of SARS-CoV-2-specific binding antibody in sera from an individual who completed two doses  
 494 of AZD1222, followed by the booster vaccine, including AZD1222 (purple), BNT162b2 (blue),  
 495 mRNA-1273 (green), or half-dose mRNA-1273 (yellow). The error bars indicate GMT and 95%  
 496 confidence intervals (95% CI). The dotted lines designate the cut-off values. ns indicates that  
 497 there is no statistical difference; \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ .




498 **Figure 3: Neutralizing activities of delta and omicron variants compared between pre-and**  
 499 **post-boost using a surrogate virus neutralization test.** A subset of samples was randomly  
 500 selected to test for sVNT, including sera collected at baseline and sera collected 28 days after  
 501 boost (n=30/group). **(A)** Neutralizing activities against the SARS-CoV-2 Delta variant and **(B)**  
 502 Neutralizing activities against the SARS-CoV-2 Omicron variant (BA.1) were shown as  
 503 %inhibition. **(C)** Comparison of the neutralizing activity between the Delta and Omicron variants  
 504 after booster vaccination. Median values with interquartile ranges (IQRs) are denoted as  
 505 horizontal bars. Horizontal bars indicate the median. Dotted lines designate cutoff values (30%).






506 **Figure 4. Neutralizing antibody titers against Omicron BA.1 and BA.2 before and after**  
 507 **booster vaccination.** Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 was measured  
 508 using the focus reduction neutralization test (FRNT50). **(A)** Neutralization against the BA.1  
 509 omicron variant and **(B)** Neutralization against the BA.2 omicron variant. **(C)** Comparison of  
 510 NAb titers against BA.1 and BA.2 on 28 days after the booster dose. **(D)** Comparison of NAb  
 511 titers against BA.1 and BA.2 on 90 days after the booster dose. Each data point represents an  
 512 individual who received a booster vaccine, including the viral vector vaccine, AZD1222

513 (purple), the mRNA vaccine, BNT162b2 (blue), mRNA-1273 (green), or half-dose mRNA-  
 514 1273 (yellow). The error bars present GMT and the 95% confidence interval (CI). Values  
 515 below the limit were substituted with a titer of 10. ns indicates that there is no statistical  
 516 difference; \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ .



517 **Figure 5. Total CD4+ and CD8+ T cell-producing IFN- $\gamma$  assay.** The QFN IFN- $\gamma$  ELISA  
 518 measured levels on days 0, 14, 28, and 90. (A) shows the IFN- $\gamma$  produced by CD4+ (stimulated  
 519 with CD4+specific epitope RBD from RBD (Ag1)) and (B) shows the IFN- $\gamma$  produced by CD4+  
 520 and CD8+ T cell (stimulated with CD4+/CD8+ specific epitope derived from S1 and S2 subunits  
 521 (Ag2)). Each data point represents an individual who received a booster vaccine, including the  
 522 viral vector vaccine, AZD1222 (purple), the mRNA vaccine, BNT162b2 (blue), mRNA-1273  
 523 (green), or half-dose mRNA-1273 (yellow). Horizontal bars indicate the median. The dotted  
 524 lines designate the cut-off values.



525

526 **Figure 6. Reactogenicity and severity of local and systemic reactions during the first seven**  
 527 **days following vaccination with a booster dose of COVID-19 vaccines.** The booster vaccine  
 528 included the viral vector vaccine – AZD1222 (A), mRNA vaccine – BNT162b2 (B), mRNA  
 529 vaccine - mRNA-1273 (C), and the half dose mRNA-1273 (D). The percentage of participants  
 530 who reported adverse events is presented on the Y axis. Swelling and redness were classified by  
 531 measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and severe ( $\geq 10$  cm).  
 532 Fever was graded as mild ( $38^{\circ}\text{C}$  to  $<38.5^{\circ}\text{C}$ ), moderate ( $38.5^{\circ}\text{C}$  to  $<39^{\circ}\text{C}$ ), and severe ( $\geq 39^{\circ}\text{C}$ ).  
 533 The other events were classified as mild (no impact on regular activity)/ moderate (some  
 534 limitation of daily activity), and severe (unable to perform or prevented daily activity).